Clinical Trials Logo

Refractory Bladder Carcinoma clinical trials

View clinical trials related to Refractory Bladder Carcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05052372 Terminated - Bladder Cancer Clinical Trials

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Start date: November 21, 2021
Phase:
Study type: Observational

Bladder cancers are associated with genetic mutations that are present in the patient's bladder or urothelium, the lining of the lower urinary tract. Fibroblast growth factor (FGFR) alterations are present in approximately one in five patients with recurrent and refractory bladder cancer. This study will collect biomarker data from subjects receiving erdafitinib to further investigate the relationship between treatment with erdafitinib and clinical response, progression, and/or genetic alterations.